Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, Baltimore, Maryland, 21201, USA.
Turkish Medicines and Medical Devices Agency, Ankara, Turkey.
AAPS PharmSciTech. 2018 Aug;19(6):2450-2458. doi: 10.1208/s12249-018-1073-5. Epub 2018 Jun 25.
In the United States (U.S.), an authorized generic (AG) drug is essentially the approved brand-name drug (i.e., innovator drug), but marketed with a different name. Like independent generics, authorized generics (AGs) generally tend to cost less than their brand name counterpart, even though AGs are essentially identical to the brand. Most patients and health professionals are unaware of the availability of AGs even though they are commonplace. The launch of an AG has a financial impact on patients and on the competitive landscape of the pharmaceutical industry. Information regarding AGs is limited. The purpose of this study is to familiarize the reader with AGs. A review of the government documents and literature was conducted. The marketing of AGs has resulted, but not always, in benefits to the patient. AGs have been used as a tool in agreements between brand and generic companies. Countries have differing allowance and approval policies for AGs. AGs have played an important role in the healthcare system.
在美国,一种被授权的仿制药实质上是已批准的品牌药物(即原研药),但采用了不同的名称进行销售。与独立仿制药一样,被授权的仿制药(AG)通常比其品牌药物的价格更低,尽管 AG 在本质上与品牌药物完全相同。尽管 AG 十分常见,但大多数患者和医疗保健专业人员都不知道它们的存在。AG 的推出对患者和制药行业的竞争格局都产生了财务影响。关于 AG 的信息有限。本研究的目的是使读者熟悉 AG。对政府文件和文献进行了审查。AG 的营销已经产生了一些益处,但并非总是如此,对患者有好处。AG 已被品牌和 generic 公司之间的协议用作工具。各国对 AG 的允许和批准政策不同。AG 在医疗保健系统中发挥了重要作用。